Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

A multidisciplinary team approach involving hematology/oncology, dermatology, and radiation oncology is optimal for the management of patients with MF and SS, particularly those with advanced disease. Informing clinicians about the recommendations outlined in the NCCN Guidelines for Primary Cutaneous Lymphomas for the diagnosis and treatment of MF and SS can help them to develop an individualized treatment plan to improve quality of life and clinical outcomes.

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.

It is important for pharmacists to understand the long-term side effects of both systemic treatment and radiation in order to provide in-depth patient counseling, as well as appropriate therapy recommendations to the multidisciplinary team.
Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.
In order to help patients make informed treatment decisions, health care professionals need to understand the clinical data regarding the indications and efficacy of novel therapies.

Pages

Subscribe to RSS - Live Webinar